- Email: [email protected]
Exam 2: Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy
Clinical Gastroenterology and Hepatology 2015;13:e51
Exam 2: Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy Test ID No.: 0220
Contact Hours: 1.0
Expiration Date: May 31, 2016
Question 1: A 45-year-old Asian male who has unresectable lung cancer comes to the oncologic clinic for consideration of chemotherapy. He has no history of liver disease and denies illicit drug use or alcohol abuse. His immunization state including Hepatitis B Virus (HBV) vaccine is up-to-date. The most recent lab results including a complete blood cell and liver enzyme (aspartate transaminase [AST] and alanine transaminase [ALT]) from 3 months ago was within normal range. The patient is concerned because he has a friend who had HBV flare after chemotherapy. What does the Center for Disease Control and Prevention currently recommend regarding HBV screening for patients undergoing chemotherapy?
a. Universal screening (ie, all patients before immunosuppressive therapy) b. Disease type-based screening (eg, patients with hematologic cancer) c. Race-based screening (eg, Asian) d. No documented recommendation
Question 2: In this study, what was the HBV screening rate in patients receiving chemotherapy at a large US academic center?
a. b. c. d. e.
<20% 20%–40% 40%–60% 60%–80% 80%
a. b. c. d. e.
Sex Age Race Type of cancer (ie, hematologic cancer) Elevated serum AST or ALT level at the initiation of chemotherapy
a. b. c. d. e.
Young adults (<40 years) Female Solid cancer White race Normal range of liver enzyme (AST or ALT)
Question 3: In this study, what was NOT associated with HBV screening in patients receiving chemotherapy?
Question 4: In this study, in which of the following subgroup, screening for HBV did NOT increase over time?
Exam 2: Low Level of Hepatitis B Virus Screening Among Patients Receiving Chemotherapy Test ID No.: 0220
Contact Hours: 1.0
Expiration Date: May 31, 2016
Question 1: A 45-year-old Asian male who has unresectable lung cancer comes to the oncologic clinic for consideration of chemotherapy. He has no history of liver disease and denies illicit drug use or alcohol abuse. His immunization state including Hepatitis B Virus (HBV) vaccine is up-to-date. The most recent lab results including a complete blood cell and liver enzyme (aspartate transaminase [AST] and alanine transaminase [ALT]) from 3 months ago was within normal range. The patient is concerned because he has a friend who had HBV flare after chemotherapy. What does the Center for Disease Control and Prevention currently recommend regarding HBV screening for patients undergoing chemotherapy?
a. Universal screening (ie, all patients before immunosuppressive therapy) b. Disease type-based screening (eg, patients with hematologic cancer) c. Race-based screening (eg, Asian) d. No documented recommendation
Question 2: In this study, what was the HBV screening rate in patients receiving chemotherapy at a large US academic center?
a. b. c. d. e.
<20% 20%–40% 40%–60% 60%–80% 80%
a. b. c. d. e.
Sex Age Race Type of cancer (ie, hematologic cancer) Elevated serum AST or ALT level at the initiation of chemotherapy
a. b. c. d. e.
Young adults (<40 years) Female Solid cancer White race Normal range of liver enzyme (AST or ALT)
Question 3: In this study, what was NOT associated with HBV screening in patients receiving chemotherapy?
Question 4: In this study, in which of the following subgroup, screening for HBV did NOT increase over time?